Clinical trial
KRN5500 in Treating Patients With Solid Tumors
NCT00017238 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00017238 |
|---|---|
| Title | KRN5500 in Treating Patients With Solid Tumors |
| Official title | A Phase I Trial of KRN5500 (NSC 650426) Given as a 72 Hour Continuous IV Infusion Every 21 Days in Patients With Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | KRN5500, pharmacological study |
| Enrollment | 40 |
| Start date | Feb 1, 2002 |
| Primary completion | Nov 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: